“I think the most exciting thing in the Sexual Medicine sphere is the stride for equity, diversity, and inclusion,” says Jesse N. Mills, MD.
In this video, Jesse N. Mills, MD, discusses 2 key UCLA studies that were presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting: "Racial and Other Social Disparities in the Treatment of Sexual Dysfunction" and "". Mills is an associate clinical professor of urology at the David Geffen School of Medicine, the director of the UCLA division of Andrology, the director of the Men’s Clinic and the chief of UCLA Santa Monica Urology, University of California, Los Angeles.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.